Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety and Efficacy of PRX 102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03018730
Recruitment Status : Active, not recruiting
First Posted : January 12, 2017
Last Update Posted : March 20, 2019
Sponsor:
Information provided by (Responsible Party):
Protalix

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : June 2019
Estimated Study Completion Date : September 2019